Evidence map›Paper›PMID 40034767›Full record

ArticlemedRxiv : the preprint server for health sciences2025

VOYAGER: an international consortium investigating the role of human papilloma virus and genetics in oral and oropharyngeal cancer risk and survival.

M Gormley, A Adhikari, T Dudding, M Pring, K Hurley, G J Macfarlane, P Lagiou, A Lagiou, J Polesel, A Agudo and 22 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

32 authors.

M GormleyMRC Integrative Epidemiology Unit, Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.ORCID 0000-0001-5733-6304
A AdhikariUniversity Hospitals Bristol NHS Foundation Trust Bristol Dental Hospital, Bristol, UK.
T DuddingMRC Integrative Epidemiology Unit, Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.ORCID 0000-0003-3756-040X
M PringBristol Dental School, University of Bristol, Bristol, UK.
K HurleyUniversity Hospitals Bristol NHS Foundation Trust Bristol Dental Hospital, Bristol, UK.
G J MacfarlaneSchool of Medicine, Medical Sciences and Nutrition, University of Aberdeen, UK.
P LagiouSchool of Medicine, National and Kapodistrian University of Athens, Greece.
A LagiouSchool of Public Health, University of West Attica, Greece.
J PoleselUnit of Cancer Epidemiology, Centro di Riferimento Oncologico di Aviano (CRO) National Cancer Institute, IRCCS, Italy.
A AgudoNutrition and Cancer Unit, Cancer Epidemiology Research Program, Catalan Institute of Oncology/IDIBELL, Barcelona, Spain.
L AlemanyInfections and Cancer Unit, Cancer Epidemiology Research Program, Catalan Institute of Oncology/IDIBELL, Barcelona, Spain.
W AhrensEpidemiological Methods and Etiological Research, Leibniz Institute for Prevention Research and Epidemiology - BIPS, Germany.
C M HealySchool of Dental Science, Dublin Dental University Hospital, Trinity College Dublin, Irel.
D I ConwaySchool of Medicine, Dentistry, and Nursing, University of Glasgow, UK.
C CanovaDepartment of Cardiac, Thoracic and Vascular Sciences University of Padova, Italy.
I HolcatovaInstitute of Hygiene and Epidemiology, Charles University Prague, Czech Republic.ORCID 0000-0002-1366-0337
L RichiardiReference Centre for Epidemiology and Cancer Prevention in Piemonte, Italy.
A ZnaorCancer Surveillance, International Agency for Research on Cancer, France.
A F OlshanDepartment of Epidemiology, Gillings School of Global Public Health, University of North Carolina, US.
R J HungProsserman Centre for Population Health Research, Lunenfeld-Tanenbaum Research Institute, Sinai Health System, Toronto, Canada.ORCID 0000-0002-4486-7496
G LiuDalla Lana School of Public Health, University of Toronto, Toronto, Canada.
S BratmanDepartment of Radiation Oncology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, Canada.
X ZhaoDepartment of Medicine, University of Tennessee, USA.
J HoltDepartment of Medicine, University of Tennessee, USA.
R CortezGenomic Epidemiology Group, World Health Organization, International Agency for Research on Cancer, Lyon, France.
V GaborieauGenomic Epidemiology Group, World Health Organization, International Agency for Research on Cancer, Lyon, France.
J D McKayGenomic Epidemiology Group, World Health Organization, International Agency for Research on Cancer, Lyon, France.
T WaterboerInfections and Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
P BrennanGenomic Epidemiology Group, World Health Organization, International Agency for Research on Cancer, Lyon, France.
N HayesDepartment of Medicine, University of Tennessee, USA.
B DiergaardeDepartment of Human Genetics, School of Public Health, University of Pittsburgh, and UPMC Hillman Cancer Center, Pittsburgh, US.
S ViraniGenomic Epidemiology Group, World Health Organization, International Agency for Research on Cancer, Lyon, France.

Funding

VECTOR CORE FACILITYP30CA047904 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI CHRISTOPHER J. BAKKENIST · 1988 to 2026
$158.0M
WILD TYPE P53-BASED ADJUVANT IMMUNOTHERAPY FOR SCCHNP50CA097190 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Heath Devin Skinner · 2004 to 2026
$49.6M
Gene Environment Interaction in Head and Neck CancerR01CA090731 · NCI · UNIVERSITY OF NORTH CAROLINA CHAPEL HILL · PI OLSHAN, ANDREW · 2001 to 2005
$4.6M
The role of germline and somatic DNA mutations in oral and oropharyngeal cancersR01DE025712 · NIDCR · INTERNATIONAL AGENCY FOR RES ON CANCER · PI BRENNAN, PAUL JOSEPH, DIERGAARDE, BRENDA B. · 2017 to 2021
$3.3M
NCI NIH HHS P30 CA047904NCI NIH HHS P50 CA097190NCI NIH HHS R01 CA090731NIDCR NIH HHS R01 DE025712
6 · The paper itself

Abstract

Head and neck cancer (HNC) is the sixth most common cancer globally. Incidence and survival rates vary significantly across geographic regions and tumor subsites. This is partly due to differences in risk factor exposure, which includes tobacco smoking, alcohol consumption and human papillomavirus (HPV) infection, alongside detection and treatment strategies. The VOYAGER (human papillomaVirus, Oral and oropharYngeal cAncer GEnomic Research) consortium is a collaboration between five large North American and European studies which generated data on 10,530 participants (7,233 cases and 3,297 controls). The primary goal of the collaboration was to improve understing of the role of HPV and genetic factors in oral cavity and oropharyngeal cancer risk and outcome. Demographic and clinical data collected by the five studies were harmonized, and HPV status was determined for the majority of cases. In addition, 999 tumors were sequenced to define somatic mutations. These activities generated a comprehensive biomedical resource that can be utilized to answer critical outsting research questions to help improve HNC prevention, early detection, treatment, and surveillance.

Indexed as

Head and neck cancerhuman papilloma virusoral canceroropharyngeal cancerrisk factorssurvival

Identifiers

PMID40034767
PMCPMC11875266

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.